$AGTC - $IMMU - $KPTI - On our trading list with news today or analyst comments with our opinion & trade ideas. Applied Genetic started with an Overweight rating. Immunomedics cited as a acquisition target. Karyopharm has it's price target raised by 2 analysts.Applied Genetic initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Applied Genetic with an Overweight rating and $14 price target. Kluska believes gene therapy is posed to be a disruptive treatment modality, with estimates exceeding $23B across these treatments in 2026. The analyst says Applied Genetic's results for X-linked retinitis pigmentosa could be best- and first-in-class, and based on market assumptions for just this program, sees ~50% upside to where the stock is currently trading.Our Take: Inexpensive Biotech with some good potential.Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim Guggenheim analyst Michael Schmidt said de-risking pipeline events, such as Immunomedics' ($IMMU) recent Trodelvy approval, can sometimes trigger M&A discussions and he sees several large Biopharma companies that have significant overlap with Trodelvy's potential target markets. Schmidt, who thinks Pfizer ($PFE), Merck ($MRK), Roche ($RHHBY) and Eli Lilly ($LLY) may be the most likely possible acquirers based on fit, need and bandwidth for a deal of this size, sees a potential $50-$60 per share acquisition price range in a theoretical M&A scenario. Based on his high conviction in Trodelvy's commercial potential in breast cancers, Schmidt keeps a Buy rating and $41 price target on Immunomedics shares.Our Take: One of our great performing picks this year along with $TGTX. We believe this analysts is correct and IMMU is an acquisition target. Selling some puts to buy some calls might be a good way to play. Even a Buy-Write-Plus options strategy could be used here.Karyopharm price target raised to $37 from $31 at JPMorganJPMorgan analyst Eric Joseph raised the firm's price target on Karyopharm Therapeutics to $37 from $31 and keeps an Overweight rating on the shares following the Xpovio label expansion for relapsed or refractory diffuse large B-cell lymphoma. The analyst anticipate a "fairly seamless" expansion of the launch and views current share levels as an attractive long-term entry point.Karyopharm price target raised to $30 from $28 at RBC CapitalRBC Capital analyst Brian Abrahams raised the firm's price target on Karyopharm to $30 from $28 and keeps an Outperform rating on the shares. After yesterday's Xpovio approval in r/r DLBCL and following additional details on the company's conference call, the analyst says he is updating his model with increased probability of success in achieving the drug's full potential in this indication at 80% vs. 60% prior. Abrahams adds that Xpovio's overall opportunity across cancers remains underappreciated in Karyopharm's valuation.Our Take: $KPTI has gotten approvals behind it now and may have more to come. A nice small cap biotech play that offers good trading opportunities. We like selling naked puts on this one. $KPTI, Karyopharm Therapeutics Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try. Trade Try2BeFunded today! .